Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report) was the target of a large growth in short interest in June. As of June 15th, there was short interest totaling 1 shares, a growth of ∞ from the May 31st total of 0 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 1,105 shares, the days-to-cover ratio is currently 0.0 days.
Starpharma Stock Down 2.6%
Starpharma stock opened at $4.56 on Wednesday. The firm’s fifty day moving average price is $4.90 and its two-hundred day moving average price is $3.65. Starpharma has a 1-year low of $0.55 and a 1-year high of $5.70.
About Starpharma
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
Featured Articles
- Five stocks we like better than Starpharma
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
